Vaxcyte, Inc. Share Price & Technical Analysis
PCVX · $47.30 (-0.19%)
Healthcare / Biotechnology
$47.30
-0.19%
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-17% return in May, 7% avg return in past 3 year May month.
11% return in 2026, 4% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 17% | 16% | -3% | -2% | -17% | – | – | – | – | – | – | – | 11% |
| 25 | 7% | -17% | -48% | -3% | -9% | -2% | 5% | -9% | 17% | 25% | 10% | 2% | -23% |
| 24 | 15% | 3% | -8% | -11% | 16% | 6% | 5% | 3% | 6% | -7% | -12% | -13% | 2% |
| 23 | -7% | -10% | -9% | 15% | 15% | 1% | -3% | 9% | -2% | -5% | 8% | 21% | 32% |
| 22 | -20% | 21% | 10% | 0% | -1% | -9% | 5% | 15% | -8% | 78% | 5% | 4% | 99% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Oversold
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$7.70B
P/E ratio
—
52W high
$65.00
52W low
$29.08
Volume
13,28,277
Beta
1.30
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Vaxcyte, Inc. share price today?
- Vaxcyte, Inc. (PCVX) last traded around $47.30 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PCVX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PCVX. Download the app for real-time alerts.
- How can I analyze Vaxcyte, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.